Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bristol-myers squibb - supozitoare - 150 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bristol-myers squibb - supozitoare - 80 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bristol-myers squibb - comprimate efervescente - 500 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bristol-myers squibb - comprimate efervescente - 330 mg + 200 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

bristol-myers squibb - comprimate efervescente - 500 mg

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - agenți antineoplazici - abraxane este indicat în monoterapie pentru tratamentul cancerului de sân metastatic la pacienții adulți care nu au reușit prima linie de tratament pentru boala metastatică și pentru care standard, conținând antraciclină terapie nu este indicat. abraxane în asociere cu gemcitabină este indicat pentru tratamentul de primă linie al pacienților adulți cu metastatic adenocarcinom de pancreas. abraxane în asociere cu carboplatină este indicat pentru tratamentul de primă linie al non-cancer pulmonar cu celule mici la pacienții adulți care nu sunt candidați pentru potențial curativ chirurgie și/sau radioterapie.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - thalidomide - mielom multiplu - imunosupresoare - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod clorhidrat de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresoare - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Uniunea Europeană - română - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - alte preparate antianemice - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.